



Cercare Medical

Papers



“Ground breaking research, a robust technology, and a market where the current technology failed to deliver what it was supposed to. That’s why we created Cercare Medical.”

Kim Beuschau Mouridsen
Founder & CEO, Cercare Medical



Østergaard et al., 2013

<https://doi.org/10.1038/jcbfm.2013.18>

Relevance of CTH and other markers in an acute ischemic stroke setting

X

Nagenthiraja et al., 2013

<https://doi.org/10.3389/fneur.2013.00140>

Retrospective evaluation of the TTP and ADC AI outlines

X

Mouridsen et al., 2013

<https://doi.org/10.1148/radiol.13121622>

Evaluation of the model based MTT outline: agreement of model outcome with neuroradiologists was 0.79

X

Hougaard et al., 2014

<https://doi.org/10.1161/STROKEAHA.113.001346>

Comparison between of remote ischemic preconditioning in addition to trombolysis therapy: inconclusive results

X



Østergaard et al., 2015

[Capillary Dysfunction: Its Detection and Causative Role in Dementias and Stroke | SpringerLink](#)

Relevance of CTH and other markers in a stroke or dementia setting

X



Engedal et al., 2018

<https://doi.org/10.1177/0271678X17721666>

MRI: COV biomarker was evaluated, named as RTH in the publication; CTH too [DSC]

X



“Ground breaking research, a robust technology, and a market where the current technology failed to deliver what it was supposed to. That’s why we created Cercare Medical.”

Kim Beuschau Mouridsen
Founder & CEO, Cercare Medical

Stenosis



Potreck et al., 2019

<https://doi.org/10.1007/s00330-019-06064-4>

CTH is a predictor of outcome for ICH in patients with acute ischemic stroke and mismatch undergoing endovascular thrombectomy

X



Brugnara et al., 2022

<https://jn.bmj.com/content/14/1/neurintsurg-2020-017163>

Comparison of maps for patients with LVO before and after endovascular treatment. T_{max} , MTT, OEF and CTH values immediately after EVT were lower in patients with complete (as compared with incomplete) recanalization

X

Kate et al., 2013

<https://doi.org/10.1038/jcbfm.2013.164>

Tested whether Blood pressure reduction impairs the perihematoma tissue oxygenation. Results revealed that blood pressure reduction does not affect perihematoma oxygen delivery.

X

Nielsen et al., 2018

<https://doi.org/10.1161/STROKEAHA.117.019740>

AI model to detect the infarct area. The infarct area was delineated by 4 expert radiologists on a T2-FLAIR scan acquired 1 month after the stroke to cross check the quality of the CNN.

X

Hansen et al., 2016

[10.1002/jmri.24963](https://doi.org/10.1002/jmri.24963)

Agreement between model and 4 expert readers.

X

Livne et al., 2018

<https://doi.org/10.1161/STROKEAHA.117.019440>

Predict final infarct from perfusion maps, T2FLAIR and DWI as seen on follow-up T2FLAIR using the extreme gradient boosting

X



“Ground breaking research, a robust technology, and a market where the current technology failed to deliver what it was supposed to. That’s why we created Cercare Medical.”

Kim Beuschau Mouridsen
Founder & CEO, Cercare Medical



Boldsen et al., 2018

<https://doi.org/10.3389/fninf.2018.00021>

Outlines of core stroke lesion using decision trees based on DWI images.

X

Neumann et al., 2009

[Interrater Agreement for Final Infarct MRI Lesion Delineation | Stroke \(ahajournals.org\)](#)

Rating infarct size with FLAIR leads to lower interrater variability than T2.

X

Jonsdottir et al., 2009

[Predicting Tissue Outcome From Acute Stroke Magnetic Resonance Imaging | Stroke \(ahajournals.org\)](#)

For AI models one should use the same amount of infarcting and non-infarcting voxels.

X

Mikkelsen et al., 2015

<https://doi.org/10.1007/s00330-015-3602-x>

Comparison between SVD method and vascular model. Vascular model can be applied to shorter scan durations.



X

Mouridsen et al. 2006

<https://doi.org/10.1016/j.neuroimage.2006.06.015>

Technical presentation of the vascular model and comparison with the traditional one



X

X

Mouridsen et al. 2014

<https://doi.org/10.1038/jcbfm.2014.111>

Technical presentation of the measure of CTH and other biomarker



X



“Ground breaking research, a robust technology, and a market where the current technology failed to deliver what it was supposed to. That’s why we created Cercare Medical.”

Kim Beuschau Mouridsen
 Founder & CEO, Cercare Medical



Tietze et al., 2015

<https://doi.org/10.1371/journal.pone.0123044>

CTH improves tumor grading and outcome prediction in glioma patients compared to CBV alone.

X

Tietze et al., 2015

<https://doi.org/10.1371/journal.pone.0202906>

Comparison between Bayesian model (BM) and Levenberg-Marquardt (LM) method for the generation of DCE perfusion maps. BM revealed superior image quality.

X



Østergaard et al. 2013

<https://doi.org/10.1158/0008-5472.CAN-13-0964>

Review article: value of biomarkers in an oncology setting

X

X

Kickingereder et al. 2020

<https://doi.org/10.1148/radiol.2020200978>

longitudinal study to evaluate bevacizumab treatment effects. The tumour metabolic rate of oxygen (TMRO2) was compared for patients treated with bevacizumab or another drug, and higher for patients treated with another drug.

X

Bonekamp et al. 2016

<https://doi.org/10.1177/0271678X16630322>

a larger TMRO₂ increases the hazards for progression and death

X

Stadlbauer et al. 2017

<https://doi.org/10.1177/0271678X17694905>

Recurrent glioblastoma had significantly higher μ VTH and μ COV as well as significantly lower mitochondrial oxygen tension (PO_{2mit}) values compared to newly-diagnosed glioblastoma




X



“Ground breaking research, a robust technology, and a market where the current technology failed to deliver what it was supposed to. That’s why we created Cercare Medical.”

Kim Beuschau Mouridsen
 Founder & CEO, Cercare Medical



Alzheimer	PAPERS	MR	CT
	<p>Madsen et al. 2022 https://doi.org/10.1016/j.nbas.2022.100035 Both Alzheimer disease and Mild Cognitive impairment patients showed increased CTH, suggesting that heterogeneity of <u>capillary blood flow</u> is a primary pathological event in Alzheimer Disease.</p>	X	
	<p>Østergaard et al. 2013 https://doi.org/10.1016/j.neurobiolaging.2012.09.011 Review paper: Model describing the sequence of adaptations that are necessary to maintain tissue oxygen metabolism when the CTH gradually increases over time in AD patients.</p>	X	X
	<p>Østergaard et al. 2015 https://doi.org/10.1007/s11910-015-0557-x Relevance of CTH and other markers in a stroke or dementia setting</p>	X	X
	<p>Nielsen et al. 2017 https://doi.org/10.1016/j.jalz.2017.02.007 CBF, CBV, MTT, CTH, COV (in the paper called RTH), and estimated tissue oxygen tension</p>	X	
	<p>Nielsen et al. 2020 https://doi.org/10.1002/dad2.12032 Focus on CTH, but MTT, CBF and CBV were also analysed</p>	X	X
Adrenoleukodystrophy			
	<p>Lauer et al. 2017 https://doi.org/10.1093/brain/awx262 focus on CTH, but also OEF and CMRO2</p>	X	




Key Publications



“Ground breaking research, a robust technology, and a market where the current technology failed to deliver what it was supposed to. That’s why we created Cercare Medical.”

Kim Beuschau Mouridsen
Founder & CEO, Cercare Medical




Stenosis		MR	CT
PAPERS	 <p>Pimentel et al., 2022 https://doi.org/10.1007/s00062-021-01077-3 Patients with asymptomatic high-grade carotid stenosis without ischemic brain lesions were evaluated before and after revascularization. High CTH was detected before revascularization and the intervention normalized CTH, CBF, OEF and MTT.</p>	X	
	<p>Kaczmarz et al., 2021 https://doi.org/10.1177/0271678X20912364 most pronounced changes of CBF and rCBV in internal carotid artery stenosis -patients were detected within individual watershed areas. Subject-specific impairments on CBF, rCBV, rOEF, CTH.</p>	X	
	 <p>Mundiyanapurath et al., 2016 https://doi.org/10.1371/journal.pone.0158148 CTH is superior to T_{max} in discriminating ICAS patients with favorable from non-favorable outcome</p>	X	
Traumatic Brain Injury			
	<p>Thorup et al., 2019 https://doi.org/10.1097/ANA.0000000000000596 Biomarkers: OEF and CMRO2 - Review article</p>	X	X
	 <p>Østergaard et al. 2014, https://doi.org/10.1038/jcbfm.2014.131 Biomarkers: Focus on CTH - Review article</p>	X	X



“Ground breaking research, a robust technology, and a market where the current technology failed to deliver what it was supposed to. That’s why we created Cercare Medical.”

Kim Beuschau Mouridsen
Founder & CEO, Cercare Medical



Cerebral small vessel disease	PAPERS	MR	CT
	<p>Østergaard et al., 2016 https://doi.org/10.1177/0271678X15606723 Review on, OEF and CMRO2 under a small vessel disease perspective CTH</p>	X	X
Covid 19	<p>Østergaard et al., 2021 https://doi.org/10.14814/phy2.14726 CTH, OEF, CMRO2</p>	X	X
Subarachnoid or intracerebral haemorrhage		X	X
	<p>Østergaard et al., 2013 https://doi.org/10.1038/jcbfm.2013.173 Relevance of CTH and other markers in Delayed Cerebral Ischemia and Chronic Degenerative Changes after Subarachnoid Hemorrhage</p>	X	X
Ischemic heart disease	<p>Østergaard et al., 2014 https://doi.org/10.1007/s00395-014-0409-x Role of capillary transit time heterogeneity in myocardial oxygenation and ischemic heart disease</p>	X	X

The logo features a large, circular ring composed of numerous small white dots, creating a textured, particle-like effect. The text 'Cercare Medical' is centered within this ring. The letter 'C' is underlined with a short horizontal line.

Cercare Medical